Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-19-024833
Filing Date
2019-04-16
Accepted
2019-04-16 19:04:00
Documents
1
Period of Report
2019-04-16

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 7897
  Complete submission text file 0001209191-19-024833.txt   10206
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 3 | Act: 34 | File No.: 001-38871 | Film No.: 19751933

Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 225 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 225 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Issuer) CIK: 0001595893 (see all company filings)

EIN.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 212-739-6400
OrbiMed Capital GP VI LLC (Reporting) CIK: 0001682115 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38871 | Film No.: 19751934